SG Americas Securities
ANIK icon

SG Americas Securities’s Anika Therapeutics ANIK Stock Holding History

SG Americas Securities’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-9,753
Closed -$147K – 2915
2025
Q1 		$147K Buy
9,753
+3,557
+57% +$59.2K ﹤0.01% 2756
2024
Q4 		$102K Sell
6,196
-3,289
-35% -$64.9K ﹤0.01% 2723
2024
Q3 		$234K Buy
9,485
+2,858
+43% +$74.1K ﹤0.01% 2363
2024
Q2 		$168K Sell
6,627
-1,988
-23% -$51.5K ﹤0.01% 2262
2024
Q1 		$219K Buy
8,615
+627
+8% +$15.2K ﹤0.01% 1909
2023
Q4 		$181K Buy
7,988
+1,341
+20% +$27.7K ﹤0.01% 2256
2023
Q3 		$124K Buy
+6,647
New +$138K ﹤0.01% 2649
2023
Q2 		– Sell
-7,358
Closed -$211K – 2269
2023
Q1 		$211K Buy
+7,358
New +$219K ﹤0.01% 2378
2022
Q1 		– Sell
-16,439
Closed -$589K – 2941
2021
Q4 		$589K Sell
16,439
-851
-5% -$34.1K ﹤0.01% 2054
2021
Q3 		$736K Buy
+17,290
New +$712K ﹤0.01% 2175
2021
Q2 		– Sell
-16,334
Closed -$666K – 2839
2021
Q1 		$666K Buy
+16,334
New +$620K ﹤0.01% 1806
2020
Q4 		– Sell
-41,849
Closed -$1.48M – 3320
2020
Q3 		$1.48M Buy
41,849
+32,811
+363% +$1.19M 0.01% 949
2020
Q2 		$341K Buy
9,038
+3,499
+63% +$115K ﹤0.01% 2423
2020
Q1 		$160K Buy
5,539
+1,169
+27% +$47.3K ﹤0.01% 2669
2019
Q4 		$227K Sell
4,370
-42,806
-91% -$2.49M ﹤0.01% 2390
2019
Q3 		$2.59M Buy
47,176
+41,421
+720% +$2.13M 0.02% 787
2019
Q2 		$234K Sell
5,755
-722
-11% -$26.3K ﹤0.01% 2328
2019
Q1 		$196K Buy
6,477
+3,235
+100% +$111K ﹤0.01% 2587
2018
Q4 		$109K Sell
3,242
-596
-16% -$21.5K ﹤0.01% 2687
2018
Q3 		$162K Sell
3,838
-2,690
-41% -$106K ﹤0.01% 2661
2018
Q2 		$209K Buy
+6,528
New +$269K ﹤0.01% 2577
2017
Q4 		– Sell
-2,041
Closed -$118K – 3170
2017
Q3 		$118K Buy
+2,041
New +$107K ﹤0.01% 3066
2017
Q1 		– Sell
-3,163
Closed -$155K – 3260
2016
Q4 		$155K Sell
3,163
-770
-20% -$35.6K ﹤0.01% 2547
2016
Q3 		$188K Buy
+3,933
New +$194K ﹤0.01% 2545
2015
Q1 		– Sell
-4,044
Closed -$165K – 2501
2014
Q4 		$165K Buy
+4,044
New +$158K ﹤0.01% 2574

Other funds holding ANIK

TI
Trigran Investments Northbrook, Illinois $545M AUM 56.2% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
AFA
Alta Fundamental Advisers New York $333M AUM 102.25% 1-Year Est. Return

SG Americas Securities's ANIK Position: Q2 2025 in Review

SG Americas Securities sold out of Anika Therapeutics (ANIK) in Q2 2025, closing a stake of 9,753 shares — an estimated $147K sold.

SG Americas Securities first reported a position in ANIK in Q4 2014 and held it in 25 quarters. The position peaked at $2.59M in Q3 2019. 103 funds tracked by Wall St. Rank hold ANIK as of Q2 2025.

  • SG Americas Securities reported no remaining Anika Therapeutics position as of Q2 2025 after selling out during the quarter.
  • SG Americas Securities sold 9,753 Anika Therapeutics shares in Q2 2025, an estimated $147K.
  • SG Americas Securities first reported a position in Anika Therapeutics in Q4 2014 and held it in 25 quarters.
  • SG Americas Securities's Anika Therapeutics position peaked at $2.59M in Q3 2019.
  • 103 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2025.

Based on SG Americas Securities's 13F filing for Q2 2025, filed 8 Aug 2025.